FibroGen, Inc. FGCL-3019-073, Phase 2, a Trial of FG 3019 Monotherapy as Neoadjuvant Treatment in Subjects with Stage I-II Squamous Non-Small Cell Lung Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Fibrogen, Inc.
Start Date
May 1, 2015
End Date
May 2, 2016
Administered By
Duke Cancer Institute
Awarded By
Fibrogen, Inc.
Start Date
May 1, 2015
End Date
May 2, 2016